摘要
目的研究SLCO1B1基因多态性对阿托伐他汀的降脂活性的影响。方法纳入初次接受阿托伐他汀治疗,用药时间超过15天且临床记录完整的,无合并应用其他影响血脂水平药物的患者。收集患者临床数据,测定患者治疗前后血脂水平,检测患者SLCO1B1-521T>C(rs4149056)和一388A>G(rs2306283)基因多态性。结果研究纳入患者56例,各位点基因型分布符合Hardy-Weinberg平衡(P>0.05)。SLCO1B1-388GG基因型亚组患者的TC、LDL-C和TG降低幅度均显著高于(AA+AG)基因型亚组患者。结论中国患者中SLCO1B1基因多态性,特别是-388A>G与阿托伐他汀药物的降脂效应相关。
Objective To study the effect of SLCOIB1 gene polymorphism on the lipid-lowering effect of atorvastatin. Methods Patients who had been taking atorvatatin for more than 15 days with complete clinical records were recruited ,and patients taking other lipid-lowering medicines or with other lipid-related factors were excluded. The clinical data and serum lipid levels before and after atorvastatin treatment were collected, and SLCOIB1 -521T〉 C （rs4149056） and -388A〉 G （rs2306283） gene polymorphisms were detected. Results The results showed that the genotype distribution of patients was consistent with the Hardy-Weinberg equilibrium （P〉0.05）. The reduction of TC, LDL-C and TG in SLCOIB1 -388GG genotype subgroup was significantly higher than that in AA＋AG genotype subgroup. Conclusion SLCOIB1 polymorphism, especially -388A〉G had significant effect on the lipid-lowering effect of atorvastatin.
出处
《中国药物警戒》
2017年第5期274-277,共4页
Chinese Journal of Pharmacovigilance
